Advanced search
Add to list

Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy

(2013) BLOOD. 122(21).
Author
Organization

Citation

Please use this url to cite or link to this publication:

MLA
Salles, Gilles André, John Francis Seymour, Pierre Feugier, et al. “Updated 6 Year Follow-up of the PRIMA Study Confirms the Benefit of 2-year Rituximab Maintenance in Follicular Lymphoma Patients Responding to Frontline Immunochemotherapy.” Blood. Vol. 122. 2013. Print.
APA
Salles, G. A., Seymour, J. F., Feugier, P., Offner, F., Lopez-Guillermo, A., Belada, D., Xerri, L., et al. (2013). Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy. BLOOD (Vol. 122). Presented at the 55th Annual meeting of the American Society of Hematology.
Chicago author-date
Salles, Gilles André, John Francis Seymour, Pierre Feugier, Fritz Offner, Armando Lopez-Guillermo, David Belada, Luc Xerri, et al. 2013. “Updated 6 Year Follow-up of the PRIMA Study Confirms the Benefit of 2-year Rituximab Maintenance in Follicular Lymphoma Patients Responding to Frontline Immunochemotherapy.” In Blood. Vol. 122.
Chicago author-date (all authors)
Salles, Gilles André, John Francis Seymour, Pierre Feugier, Fritz Offner, Armando Lopez-Guillermo, David Belada, Luc Xerri, Reda Bouabdallah, John Catalano, Brice Pauline, Dolores Caballero, Corinne Haioun, Lars Møller Pedersen, Alain Delmer, David Simpson, Sirpa Leppa, Pierre Soubeyran, Anton Hagenbeek, Olivier Casasnovas, Tanin Intragumtornchai, Christophe Ferme, Maria Gomes da Silva, Catherine Sebban, Andrew Lister, Jane A Estell, Gustavo Milone, Anne Sonet, Bertrand Coiffier, and Nerve Tilly. 2013. “Updated 6 Year Follow-up of the PRIMA Study Confirms the Benefit of 2-year Rituximab Maintenance in Follicular Lymphoma Patients Responding to Frontline Immunochemotherapy.” In Blood. Vol. 122.
Vancouver
1.
Salles GA, Seymour JF, Feugier P, Offner F, Lopez-Guillermo A, Belada D, et al. Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy. BLOOD. 2013.
IEEE
[1]
G. A. Salles et al., “Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy,” in BLOOD, New Orleans, LA, USA, 2013, vol. 122, no. 21.
@inproceedings{5792633,
  articleno    = {abstract 509},
  author       = {Salles, Gilles André and Seymour, John Francis and Feugier, Pierre and Offner, Fritz and Lopez-Guillermo, Armando and Belada, David and Xerri, Luc and Bouabdallah, Reda and Catalano, John and Pauline, Brice and Caballero, Dolores and Haioun, Corinne and Pedersen, Lars Møller and Delmer, Alain and Simpson, David and Leppa, Sirpa and Soubeyran, Pierre and Hagenbeek, Anton and Casasnovas, Olivier and Intragumtornchai, Tanin and Ferme, Christophe and da Silva, Maria Gomes and Sebban, Catherine and Lister, Andrew and Estell, Jane A and Milone, Gustavo and Sonet, Anne and Coiffier, Bertrand and Tilly, Nerve},
  booktitle    = {BLOOD},
  issn         = {0006-4971},
  language     = {eng},
  location     = {New Orleans, LA, USA},
  number       = {21},
  title        = {Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy},
  volume       = {122},
  year         = {2013},
}

Web of Science
Times cited: